MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. - Wikidata - awgldk - TriplyDB

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

http://www.wikidata.org/entity/Q35196526

about

Development of cell-cycle checkpoint therapy for solid tumors Targeting the Checkpoint to Kill Cancer Cells Improving the efficacy of chemoradiation with targeted agents Emerging Treatment Paradigms in Radiation Oncology Synthetic lethal screens as a means to understand and treat MYC-driven cancers Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer Functional kinomics identifies candidate therapeutic targets in head and neck cancer Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.WEE1 tyrosine kinase, a novel epigenetic modifier Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Radiosensitization in prostate cancer: mechanisms and targets Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Targeting lung cancer through inhibition of checkpoint kinases.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.Enhancement of Radiation Sensitivity in Lung Cancer Cells by a Novel Small Molecule Inhibitor That Targets the β-Catenin/Tcf4 Interaction Drosophila Cancer Models Identify Functional Differences between Ret Fusions.Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine Translational and clinical implications of the genetic landscape of prostate cancer.Wee1 kinase as a target for cancer therapy.Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.

P2860

Q26781187-ABC56E01-CBF4-477A-9D39-9C03C5889E16 Q26795781-C087A7B1-1337-43CB-A9E5-B1F6D2129C96 Q26850193-DCFD4C1C-3ED8-44E8-86AC-6E16EFBB769B Q26853461-9185387A-7637-495D-A06E-D3681B2E2BD2 Q27006010-85BC5D8D-BE0C-41A6-8E07-A7DF050F65FA Q27023686-A029C1F9-2ACF-4896-8C2C-41E7439CBE2F Q27323300-4DC4F928-0D10-4548-A7A5-F4BF26EB4CDE Q28078268-C91665CE-7425-487E-B9FA-5D73499875BE Q28260029-F8077750-5A2C-4163-B2A0-8F3612E898EB Q28818350-4C60B1FD-FB1B-4151-B776-B4691225CFAE Q33570786-1920AEDD-6028-427A-B685-56826B6E84F9 Q33946208-6B3D20DB-2CD8-48EE-9CE6-DBCB87B8B30A Q34055936-F145C7D0-3258-4182-88AA-BC1BE9FBEF6C Q34104143-6BDEDC89-3A11-4FB8-9DD4-A504D3565858 Q34287982-FCA9722E-B9D0-4BAE-BC19-F379D1035889 Q34335765-BB894262-EE38-4B6B-9246-2009D50BB79E Q34352858-31C3785E-D407-47EC-B78A-ABA0A5F679A1 Q34404877-E0D98055-2836-4C65-A429-56CF2979DD4C Q34544769-A92320F3-E804-4569-8D6B-408492E4BC05 Q34563981-16C5F3C8-689B-447F-B0AE-AEDEC548B59E Q34808616-E4AA8CC5-AC34-4E78-9B86-A8CAF6E258FB Q35128547-BFDEF6F6-7B03-4997-9381-AD85420CEFA9 Q35287823-A269B312-70B5-4F02-94CF-CE3CD6B5838D Q35463482-E16EBB9D-1EBE-459F-A898-D186487F3E9C Q35856816-F45EAEF3-0398-40AA-B70E-3B7D5FF72373 Q35970241-CC3CBCC1-23B2-4140-B249-06B985F552CB Q36132331-50F6B155-2EC7-4373-B24D-E329EB87BEC5 Q36162494-CCD99C8A-CAD9-429D-9024-8A064490C6C8 Q36244669-1AC46039-C795-40D7-A234-42B7C4BAD272 Q36309585-663319B6-9336-41CF-8A4A-648614A79D03 Q36341628-B911698F-4D78-4295-B3BE-0D77A6A0DCDF Q36454659-8B07D3B9-8787-44AE-9F11-D51C06CE2BB4 Q36843733-7D58B2AF-97E0-4B3A-8F09-51F68D3249BF Q36943880-BD0EA7B1-1810-4928-BAD8-DFC2F4ED7223 Q37075297-4771F268-7329-4FA3-BE54-EE214487662D Q37230991-8EFD73CE-C92E-46E7-90FA-2D1E9C5896EA Q37270512-474BE6BF-C5BF-4A2F-86E7-1EFA9021F100 Q37396839-A218D0B7-1AB0-492E-9343-A37F2979479C Q37499287-AE760D31-F707-4957-994B-BBD9D72A614E Q37580332-93CB4E5A-C350-4BA4-B5E7-87B5C339D174

P2860

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

http://www.wikidata.org/entity/Q35196526

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@ast

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@en

type

label

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@ast

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@en

prefLabel

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@ast

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

@en

P1433

Q35196526-3368B275-568E-4D5F-88C5-3AF286E513A7

P1476

Q35196526-14699A27-85E7-4A9C-B533-34E963293054

P2093

Q35196526-179EC22F-71B7-45AC-B682-79FC769A970D

Q35196526-59220B24-92D9-47FD-8A12-4613696BEFE2

Q35196526-73375539-D035-4F13-9657-C85211F5243E

Q35196526-88129001-A568-41EF-9AF3-02AE214F1DA1

Q35196526-95424461-2CED-4994-93DB-A9E11D0F50D9

Q35196526-9F31DCAE-824B-4C35-B87F-EE626796335C

Q35196526-A7C75468-4BE3-4584-9700-A68BF7073947

Q35196526-AA8F2E6B-9109-4DDB-AC22-1F61E17DCF59

P2860

Q35196526-0D130C80-0401-4E80-8CEE-BE996D1DF80F

Q35196526-0DD31A22-7341-4BBF-9EED-4ECEC90482C4

Q35196526-11358553-40E2-44E5-A45E-05D5FF4F5FB4

Q35196526-1E6B2129-7616-4606-A0E3-818ED5ED4FE1

Q35196526-2D3AA5B0-4F17-44D6-8FDF-B28D40A7B32A

Q35196526-421A71D8-0E9D-400D-B290-4CE33A016ED7

Q35196526-47239285-EAD5-4024-9B98-F9C80B4D4312

Q35196526-53586A02-852F-4998-85F3-B41E71B382B6

Q35196526-688A077A-2D1F-4025-ADD6-C5D15B269F30

Q35196526-75E269B8-B8F8-4AAC-AC16-23A3119D8E36

P304

Q35196526-07CADB30-E44A-498E-B537-7497443F92BB

P31

Q35196526-E8BE22C4-5810-4535-82E3-01EC57324722

P356

Q35196526-E1AED2EB-5DBD-479F-A40F-D68B8FF6E016

P407

Q35196526-EE9A3F1F-5CB3-4164-8A07-5FD77E3D6CF2

P433

Q35196526-D3BED545-1EB2-4756-A2E6-356992B77D1B

P478

Q35196526-17B62150-1114-46E0-AC76-147A5F9980DB

P50

Q35196526-E0528EF7-DA4A-41E9-88A7-384B1073491C

P577

Q35196526-87F029B9-B215-41A9-8E88-45B357918D79

P5875

Q35196526-E0600990-7E69-42B8-861D-CAB462D07D96

P698

Q35196526-D028A0FE-60F9-4B6D-846A-B111F89A7B1C

P932

Q35196526-908DAFD9-F869-40E8-BE8F-53351A8F44B6

P356

1078-0432.CCR-11-0650

P1433

Clinical Cancer Research

P1476

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells

@en

P2093

Carolyn A Buser

http://www.w3.org/2001/XMLSchema#string

Colin Brooks

http://www.w3.org/2001/XMLSchema#string

Hiroshi Hirai

http://www.w3.org/2001/XMLSchema#string

Huifeng Liu

http://www.w3.org/2001/XMLSchema#string

Kathleen A Bridges

http://www.w3.org/2001/XMLSchema#string

Kathryn A Mason

http://www.w3.org/2001/XMLSchema#string

Raymond E Meyn

http://www.w3.org/2001/XMLSchema#string

Thomas A Buchholz

http://www.w3.org/2001/XMLSchema#string

P2860

p53, the cellular gatekeeper for growth and division

The DNA damage response: putting checkpoints in perspective

Control of the G2/M transition

Cell cycle checkpoints: preventing an identity crisis

Live or let die: the cell's response to p53

Universal control mechanism regulating onset of M-phase

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint.

Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation.

Regulation of the G2/M transition by p53.

P304

5638-5648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0650

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Jessica M Molkentine

P577

2011-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51530458

http://www.w3.org/2001/XMLSchema#string

P698

21799033

http://www.w3.org/2001/XMLSchema#string

P932

3167033

http://www.w3.org/2001/XMLSchema#string